Lv1
16 积分 2024-09-30 加入
A Proportional Hazards Model for the Subdistribution of a Competing Risk
26天前
已完结
Regression modeling of competing risk using R: an in depth guide for clinicians
26天前
已完结
Competing risk analysis using R: an easy guide for clinicians
26天前
已完结
Venetoclax plus D-CAG (decitabine, cytarabine, aclarubicin, G-CSF) for elderly or unfit patients with newly diagnosed acute myeloid leukemia: a multicenter, prospective study
3个月前
已完结
Decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin is as effective as standard dose chemotherapy in the induction treatment for patients aged from 55 to 69 years old with newly diagnosed acute myeloid leukemia
3个月前
已完结
10-day decitabine versus 3 + 7 chemotherapy followed by allografting in older patients with acute myeloid leukaemia: an open-label, randomised, controlled, phase 3 trial
4个月前
已完结
10-day decitabine versus 3 + 7 chemotherapy followed by allografting in older patients with acute myeloid leukaemia: an open-label, randomised, controlled, phase 3 trial
4个月前
已完结
Acute Myeloid Leukemia Patients with High-Risk Karyotypes Benefit from Decitabine in Combination with Modified CAG
4个月前
已完结
Epigenetic modifier gene mutations‐positive AML patients with intermediate‐risk karyotypes benefit from decitabine with CAG regimen
4个月前
已完结
The effect of granulocyte-colony stimulating factor, decitabine, and busulfan–cyclophosphamide versus busulfan–cyclophosphamide conditioning on relapse in patients with myelodysplastic syndrome or secondary acute myeloid leukaemia evolving from myelodysplastic syndrome undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised, phase 3 trial
9个月前
已完结
皖公网安备34019202002308
